Anchoring Phase I Clinical Trial Design in the Final Evidence Package

In early-phase development, decisions around the first-in-human (FIH) studies made for short-term momentum can inadvertently create a dataset that is harder to defend later. Rapid design and activation without a clear regulatory endpoint may allow a study to reach the clinic sooner, but it can also leave unresolved questions that resurface during downstream due diligence.

Protocols shaped primarily around speed-to-clinic metrics can leave uncertainty around how the outcomes will direct next steps, or may not realize the potential value of the asset. When those gaps resurface during scientific advice, they potentially create avoidable work before the next clinical stage.

For biotech teams managing finite capital, strong Phase I design generates evidence that can help solidify regulatory and financing decisions. Reverse journey mapping builds that discipline by treating the intended evidence package as the reference point when embarking on early clinical design.

Starting with the destination clarifies data required to achieve this outcome and helps teams remove unnecessary noise in data that may not be as valued, so the emerging evidence will withstand future scrutiny from regulators such as the FDA and European Medicines Agency (EMA).

The commercial consequences of undefined regulatory endpoints

Clinical development teams operate under real-time pressure to reach evidence-generating milestones before cash runways expire. In a Tufts Center for the Study of Drug Development survey of more than 400 industry respondents, the overall study start-up process averaged 5 to 6 months, with contract research organizations (CROs) completing site-related activities 6 to 11 weeks faster than sponsors.¹

Speed protects a program only when early decisions remain anchored to a clear development strategy. Without a defined regulatory destination, sponsors may diversify early-phase protocols to accommodate too many possible development paths.

As a result, protocols accumulate assessments and data without a clear view of how each variable supports the next clinical milestone. Collecting broad data without a defined outcome can obscure data clarity.

Ambiguity may create friction during downstream scientific advice and due diligence, requiring stakeholders to reconstruct the logic behind earlier decisions. For investor-backed biotechs relying on Phase I data to secure financing or advance into Phase II, this friction can create costly supplementary work.

Those unplanned activities place pressure on capital and delay commercial momentum.

Designing quality into the evidence pathway

The operational consequences of an unclear evidence pathway are not limited to study execution. They begin at the point of protocol design, in which quality-by-design principles help determine whether data can support later regulatory decisions and stand up to ever-increasing standards and regulatory rigor.

Aligning study design and conduct with international ethical and scientific quality standards establishes a defensible foundation from the outset.^2,3 Selecting the appropriate study population or dose exploration strategy shapes the claims a sponsor can ultimately defend to regulators.

Finalizing these variables before clarifying the intended regulatory pathway has the potential to embed quality risks into the study architecture. Quality-by-design principles focus attention on the factors that are critical to data quality and remove features that do not support the study’s purpose.

Reverse journey mapping applies that discipline to the full development pathway by defining the future evidence first. That sequence identifies the questions that require resolution before execution begins.

Assigning study endpoints that do not guide subsequent development decisions can produce commercially incompatible data. By designing the protocol to align with commercial needs, sponsors can build success into the process from the first day of development.

Such discipline depends on early alignment between clinical delivery and regulatory strategy. Regulatory foresight clarifies the global evidence standard.

Operational input tests whether the design can be executed in the real world. Aligning these functions before execution begins helps data translate scientific questions into analyzable outcomes, creating a stronger foundation for the clinical program.

Transforming final regulatory requirements into foundational trial architecture

Reverse journey mapping anchors early study design in the final evidence package. Prioritizing the evidence required to remain credible as scrutiny increases informs the trial architecture.

This approach makes the intended submission the primary reference point for early clinical decisions.

In practice, this process begins by defining the product’s intended use and likely place in clinical practice. Isolating the target patient population and real-world delivery context clarifies the therapeutic claims the product may eventually support.

These foundational decisions guide the evidence required at each development stage. Designing study objectives around these core questions helps remove variables that lack a clear regulatory purpose.

A rigorously defined Target Product Profile (TPP) supports this operational discipline. Defining the TPP early anchors near-term clinical activity to longer-term commercial and regulatory objectives.

As evidence develops, the TPP gives teams a structured way to test whether new findings still support the intended regulatory and commercial pathway. This strategic development tool keeps the clinical program aligned with final labeling and regulatory expectations.⁴

Early-stage targets often shift as new evidence emerges, so development teams need a framework for managing change. Emerging evidence from clinical practice can alter assumptions made and evidence standards.

Reverse journey mapping provides a structural baseline for assessing these variables, helping program adaptations remain aligned with the intended regulatory and commercial pathway.

Aligning trial architecture with downstream regulatory expectations

Once the intended evidence package is defined, reverse journey mapping becomes a practical design tool for the early phase protocol. Targeting a specific patient population defines protocol parameters and early enrollment choices establish how directly FIH findings inform downstream development.

When key safety or pharmacology questions depend on disease context, evaluating participants within that context can generate a more targeted evidence package for regulatory review. Early dose strategy establishes the foundation for long-term regulatory acceptability.

Initiatives such as the FDA’s Project Optimus emphasize regulatory scrutiny on dose optimization and dose selection from the earliest clinical stages.^5,6 This heightened focus reinforces the need for robust evidence behind early dose decisions, particularly when historical approaches provide an incomplete view of benefit-risk balance.

Precise endpoint selection supports clearer development decisions. It allows sponsors to integrate specific pharmacokinetic and pharmacodynamic signals alongside core safety and tolerability measures.

This builds a more useful data package for subsequent phases when those signals are being translated into showing direct clinical effect as hypothesized from the beginning. Consistently capturing these measures reduces interpretive uncertainty and protects clinical momentum.

Initial data structures influence long-term international viability. Generating early data without standards that anticipate later review can force sponsors to retrofit documentation and analysis structures before formal regulatory interactions.

This administrative rework may expose gaps in the original rationale, delaying submissions. Designing early data parameters for future international review helps create coherent, globally defensible data.

Generating globally credible data with efficiency

Australia can provide an efficient setting for early-phase clinical development when the study is designed as part of a broader global pathway. Under the Therapeutic Goods Administration’s Clinical Trial Notification (CTN) scheme, the Australian clinical trial sponsor submits a notification to the Health Agency, and is primarily responsible for ensuring Human Research Ethics Committee and institutional approvals are in place before the unapproved therapeutic good is supplied in the trial.⁷

This pathway supports efficient initiation when the study is appropriately designed and governed. Australia’s strategic value extends beyond rapid start-up timelines.

Connecting early clinical activity to a broader global pathway helps sponsors use Australia’s early-phase advantages more strategically. Designing the study to support future FDA and EMA discussions builds a more internationally defensible evidence base.

This distinction is central to Australia’s role as a strategic launchpad. A pragmatic regulatory environment does not equate to a lower evidence standard.

Australia adds the most value when trial activation, endpoint selection and data collection remain aligned with the evidence expectations sponsors will face beyond the first readout. Aligning Australian study activation with global evidence expectations supports early clinical data generation at pace and with discipline.

This operational discipline positions Australia as a strategic enabler within a broader global development pathway.

Securing predictable progress through disciplined protocol design

Phase I design establishes the foundational evidence standard for the program. Funding pressures often prioritize speed-to-clinic metrics. Validating key design choices against downstream regulatory expectations provides a more accurate measure of commercial momentum.

Before a Phase I protocol is locked, sponsors need a clear rationale for how the study supports the next regulatory and financing decision. That clarity gives teams a more useful measure of progress than speed alone.

Reverse journey mapping builds this clarity into the clinical architecture. Anchoring the protocol in the intended submission defines which variables to measure and which to exclude.

By bringing clinical delivery and regulatory foresight into alignment earlier, the risk of identifying crucial data gaps at a later stage is reduced. For biotech teams, applying reverse journey mapping aligns early clinical design directly with capital efficiency and international regulatory readiness.

Designing a study from the final evidence package backwards yields a documented foundation for the key decisions that shape the asset’s next stage of development.

Securing clinical momentum

Building regulatory readiness into early-stage clinical development accelerates asset entry into the clinic, but true success is measured by patient impact. Reverse journey mapping bridges the gap between rapid trial activation and long-term regulatory compliance.

By aligning early clinical strategy with definitive endpoints, this approach helps sponsors secure the data needed for future phases while focusing on the therapeutic outcomes that matter most to patients waiting for new treatment options.

About the Author

Greg Plunkett is CEO and Managing Director of Accelagen.

References

1. Lamberti MJ, Wilkinson M, Harper B, et al. Assessing study start-up practices, performance, and perceptions among sponsors and contract research organizations. Ther Innov Regul Sci. 2018;52(5):572-578. doi:10.1177/2168479017751403
2. International Council for Harmonisation. E8(R1) general considerations for clinical studies. Adopted October 6, 2021. Accessed June 16, 2026. https://database.ich.org/sites/default/files/E8-R1_Guideline_Step4_2021_1006.pdf
3. International Council for Harmonisation. E6(R3) guideline for good clinical practice. Adopted January 6, 2025. Accessed June 16, 2026. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
4. U.S. Food and Drug Administration. Target Product Profile — a strategic development process tool: guidance for industry and review staff. Draft guidance. Published March 2007. Accessed June 16, 2026. https://www.fda.gov/media/72566/download
5. U.S. Food and Drug Administration. Project Optimus. Accessed June 16, 2026. https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus
6. U.S. Food and Drug Administration. Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases: guidance for industry. Published August 2024. Accessed June 16, 2026.https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases
7. Therapeutic Goods Administration. Clinical Trial Notification scheme. Accessed June 16, 2026. https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/clinical-trials/clinical-trial-notification-ctn-scheme